Company intelligence / Profile preview
Ailux Biologics
Somerville, MA, United Statesailux.xtalpi.com ↗
- Ownership
- Private
- Employees
- ~100
- Development stage
- Preclinical
01
Overview
Ailux Biologics has established a robust AI-powered platform validated through over 30 internal and partner programs. Their lead therapeutic candidate, SIGX1094, is in Phase I trials targeting diffuse gastric cancer and other advanced solid tumors. The company has entered into major licensing agreements with Janssen Biotech and UCB to deploy its AI platforms for accelerated biologic drug discovery.
- Therapeutic areas
- OncologyImmunologyInfectious Diseases
- Modalities
- Monoclonal antibodyBispecific monoclonal antibodyAntibody-drug conjugateProtein
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Janssen Biotech / Johnson & Johnson InnovationUCBSignet Therapeutics
Beyond the preview
Go deeper on Ailux Biologics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ailux Biologics.